Home Markets Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

1

PARIS & BOSTON–()–Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today unveiled the next-generation Cellvizio platform, which has already received both 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking. Built with enhanced capabilities, this entirely new system uses the company’s proprietary Confocal Laser Endomicroscopy (CLE) advanced imaging technology to deliver cellular and molecular imaging virtually anywhere in the human body, and will be available for purchase in the second half of 2021.

Building upon the success of the previous models, the new generation of Cellvizio equips physicians with the most advanced cellular imaging technology to improve patients’ lives. The platform includes several new features: an all-new…

Click here for full article…www.businesswire.com